Analyst Price Target is $6.17
▲ +12.94% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for OncoCyte in the last 3 months. The average price target is $6.17, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 12.94% upside from the last price of $5.46.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in OncoCyte. This Buy consensus rating has held steady for over two years.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.